Skip to main content
Year archive

Medivir — 2011 filings

All 79 regulatory filings released by Medivir (MVIR) in 2011, sourced directly from the official regulator.

79 Filings
2011 Period
2011 filings (79)
Filing Released Lang
Medivir - TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients
Regulatory Filings
2011-12-02 English
Medivir - TMC435 kommer att utvärderas i en fas II-studie i kombination med daclatasvir (BMS-790052) i patienter med HCV av genotyp 1
Regulatory Filings
2011-12-02 Swedish
Major Shareholding Notification 2011
Major Shareholding Notification
2011-12-01 English
Major Shareholding Notification 2011
Major Shareholding Notification
2011-11-28 English
Key news from the ongoing Capital Markets Day
Regulatory Filings FY 2011
2011-11-15 English
Huvudnyheter från pågående kapitalmarknadsdag
Regulatory Filings
2011-11-15 Swedish
Medivir’s partner Tibotec announced that final SVR24 results from phase IIb PILLAR study of TMC435 will be presented at the AASLD meeting today
Investor Presentation
2011-11-07 English
Medivirs partner Tibotec meddelar att slutliga SVR24-resultat från fas IIb-studien PILLAR med TMC435 kommer att presenteras idag på AASLD-mötet
Regulatory Filings
2011-11-07 Swedish
Medivir offentliggör slutresultat från TMC435 fas IIb-studien ASPIRE (C206)
Earnings Release FY 2011
2011-11-02 Swedish
Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study
Earnings Release FY 2011
2011-11-02 English
Interim / Quarterly Report 2011
Interim / Quarterly Report 9M 2011
2011-10-24 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report 9M 2011
2011-10-24 English
Major Shareholding Notification 2011
Major Shareholding Notification
2011-10-14 English
Medivir offentliggör att fyra TMC435-abstrakt accepterats för presentation på AASLD:s möte
Investor Presentation
2011-09-30 Swedish
Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the AASLD Meeting
Regulatory Filings
2011-09-30 English
Maris Hartmanis ny verkställande direktör för Medivir
Board/Management Information
2011-09-26 Swedish
Maris Hartmanis appointed new CEO of Medivir
Board/Management Information
2011-09-26 English
Completed Enrollment of Three Global Phase 3 Trials for TMC435 in Chronic Hepatitis C Genotype-1 Infected Patients
Regulatory Filings
2011-08-31 English
Fullbordad rekrytering för tre globala fas 3-studier för TMC435 i patienter infekterade med kronisk hepatit C (HCV) av genotyp-1
Regulatory Filings
2011-08-31 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report H1 2011
2011-08-31 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report H1 2011
2011-08-31 English
Medivir stärker sin ledningsgrupp
Board/Management Information
2011-08-30 Swedish
Medivir Strengthens its Management Team
Board/Management Information
2011-08-30 English
Medivirs dotterbolag, BioPhausia AB, har avyttrat sin generikaverksamhet
M&A Activity
2011-08-26 Swedish
Medivir subsidiary BioPhausia AB sells generics business
Regulatory Filings
2011-08-26 English
Number of shares and votes in Medivir
Share Issue/Capital Change
2011-07-29 English
Antal aktier och röster i Medivir
Share Issue/Capital Change
2011-07-29 Swedish
TMC435 has Received Fast Track Designation from the FDA and TMC435 will be studied in combination withPharmasset's PSI-7977 for HCV genotype-1
Regulatory Filings
2011-07-06 English
TMC435 har beviljats ”Fast Track” status av FDA och TMC435 kommer att ingå i en kombinationsstudie med Pharmassets PSI-7977 för HCV genotyp 1
Regulatory Filings
2011-07-06 Swedish
Ökat antal aktier och röster i Medivir
Share Issue/Capital Change
2011-06-30 Swedish
Increased number of shares and votes in Medivir
Share Issue/Capital Change
2011-06-30 English
Medivir erhåller 45 miljoner USD från Meda för de amerikanska rättigheterna till Xerese™
Capital/Financing Update
2011-06-29 Swedish
Medivir Receives $45 million from Meda for US rights for Xerese™
Capital/Financing Update
2011-06-29 English
Medivir undertecknar distributionsavtal med Daewoong för Xerclear® i Kina och Hongkong
Regulatory Filings
2011-06-23 Swedish
Medivir signs agreement with Daewoong to distribute Xerclear® in China and Hong Kong
Regulatory Filings
2011-06-23 English
TMC649128 enters Phase Ib Trial in Patients Chronically Infected with Genotype-1 Hepatitis C Virus
Regulatory Filings
2011-06-22 English
Klinisk fas Ib-studie med TMC649128 inleds i patienter med kronisk Hepatit C-virusinfektion av genotyp-1
Regulatory Filings
2011-06-22 Swedish
Medivir innehar 94 procent av aktierna i BioPhausia efter den slutliga acceptfristens utgång
AGM Information
2011-06-16 Swedish
Medivir holds 94 per cent of the shares in BioPhausia following the expiry of the final acceptance period
M&A Activity
2011-06-16 English
Påminnelse: Sista dag för accept av budet på BioPhausia är den 14 juni – kommer inte att förlängas
M&A Activity
2011-06-13 Swedish
Reminder: last day for acceptance of the offer for BioPhausia is 14 June – will not be extended
M&A Activity
2011-06-13 English
Medivir fullföljer budet på BioPhausia och förlänger acceptfristen
AGM Information
2011-06-01 Swedish
Medivir completes the offer for BioPhausia and extends the acceptance period
M&A Activity
2011-06-01 English
Medivir offentliggör tillägg till erbjudandehandling avseende budet på BioPhausia samt förlänger acceptfristen
M&A Activity
2011-05-23 Swedish
Addendum to offer document made public regarding Medivir’s offer for BioPhausia and extension of the acceptance period
M&A Activity
2011-05-23 English
Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients
Earnings Release FY 2011
2011-05-20 English
Rättelse
Regulatory Filings
2011-05-16 Swedish
Medivir offentliggör tillägg till erbjudandehandling avseende budet på BioPhausia
M&A Activity
2011-05-10 Swedish
Beslut vid årsstämma samt extra bolagsstämma i Medivir den 5 maj 2011
AGM Information
2011-05-05 Swedish
Resolutions at the annual and extraordinary general meetings in Medivir on 5 May 2011
AGM Information
2011-05-05 English
Interim / Quarterly Report 2011
Interim / Quarterly Report Q1 2011
2011-05-05 Swedish
Earnings Release 2011
Earnings Release Q1 2011
2011-05-05 English
Medivir offentliggör erbjudandehandling avseende budet på BioPhausia
M&A Activity
2011-04-29 Swedish
Major Shareholding Notification 2011
Major Shareholding Notification
2011-04-28 English
Notice of Extraordinary General Meeting of Medivir AB (publ)
AGM Information
2011-04-11 English
Kallelse till extra bolagsstämma i Medivir AB (publ)
AGM Information
2011-04-11 Swedish
Annual Report 2010
Annual Report FY 2010
2011-04-06 Swedish
Annual Report 2010
Annual Report FY 2010
2011-04-06 English
Kallelse till årsstämma i Medivir AB (publ)
AGM Information
2011-04-05 Swedish
Notice of Annual General Meeting of Medivir AB (publ)
AGM Information
2011-04-05 English
Medivir: Week 24 Interim Results from TMC435 Hepatitis C Phase 2b ASPIRE Study presented at EASL
Earnings Release FY 2011
2011-04-01 English
Medivir: Interimsdata från vecka 24 av TMC435 hepatit C fas 2b-studien ASPIRE har presenterats vid EASL
Earnings Release FY 2011
2011-04-01 Swedish
Increased number of shares and votes in Medivir
Share Issue/Capital Change
2011-03-31 English
Ökat antal aktier och röster i Medivir
Share Issue/Capital Change
2011-03-31 Swedish
Major Shareholding Notification 2011
Major Shareholding Notification
2011-03-17 English
Major Shareholding Notification 2011
Major Shareholding Notification
2011-03-03 English
Medivirs munsårsläkemedel Xerese™ lanseras nu i USA
Regulatory Filings
2011-03-01 Swedish
Medivir’s Cold Sore Treatment Xerese™ Now Launched in the United States
Regulatory Filings
2011-03-01 English
Major Shareholding Notification 2011
Major Shareholding Notification
2011-02-25 English
Earnings Release 2010
Earnings Release FY 2010
2011-02-22 Swedish
Audit Report / Information 2010
Audit Report / Information FY 2010
2011-02-22 English
Medivir Announces positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-naïve Patients
Earnings Release FY 2011
2011-02-22 English
Medivir offentliggör positiva interimsresultat (SVR24) från fas 2b-studie omfattande 48 veckors behandling med TMC435 på behandlingsnaiva patienter
Earnings Release FY 2011
2011-02-22 Swedish
The phase 3 program for TMC435 in treatment-naïve patients and patients who have relapsed after prior interferon-based treatment has now started
Regulatory Filings
2011-02-18 English
Fas 3-program för behandling med TMC435 i behandlingsnaiva patienter och i patienter som återinsjuknat har nu startat
Regulatory Filings
2011-02-18 Swedish
Medivir inleder ett forsknings- och utvecklingssamarbete inriktat på denguevirus
Regulatory Filings
2011-02-14 Swedish
Medivir Signs Research & Development Collaboration on Dengue Virus
Regulatory Filings
2011-02-14 English
Medivir offentliggör start av klinisk fas 1a-studie med polymerashämmaren TMC649128 mot hepatit C
Regulatory Filings
2011-02-10 Swedish
Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128
Regulatory Filings
2011-02-10 English